Joseph Slattery Buys 16,000 Shares of ImageneBio (NASDAQ:IMA) Stock

ImageneBio, Inc. (NASDAQ:IMA) Director Joseph Slattery bought 16,000 shares of ImageneBio stock in a transaction on Wednesday, December 24th. The stock was acquired at an average price of $5.99 per share, for a total transaction of $95,840.00. Following the transaction, the director directly owned 16,000 shares of the company’s stock, valued at approximately $95,840. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

ImageneBio Trading Up 10.5%

ImageneBio stock traded up $0.61 during midday trading on Monday, reaching $6.41. 352,363 shares of the stock traded hands, compared to its average volume of 33,598. The firm has a market cap of $71.68 million, a PE ratio of -0.79 and a beta of 0.44. ImageneBio, Inc. has a 12-month low of $5.70 and a 12-month high of $20.40. The company has a 50-day simple moving average of $7.23 and a two-hundred day simple moving average of $11.06.

ImageneBio (NASDAQ:IMA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.91) EPS for the quarter, missing analysts’ consensus estimates of ($1.47) by ($1.44). Equities research analysts anticipate that ImageneBio, Inc. will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On ImageneBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its stake in shares of ImageneBio by 62.4% in the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock valued at $98,000 after purchasing an additional 29,369 shares during the period. Bridgeway Capital Management LLC purchased a new position in ImageneBio in the 3rd quarter valued at about $104,000. NewEdge Advisors LLC acquired a new stake in shares of ImageneBio during the third quarter valued at about $106,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of ImageneBio during the third quarter valued at about $144,000. Finally, Aldebaran Capital LLC purchased a new stake in shares of ImageneBio during the third quarter worth about $159,000. 75.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on IMA shares. Wall Street Zen downgraded shares of ImageneBio from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Leerink Partners started coverage on ImageneBio in a report on Friday, October 24th. They issued an “outperform” rating and a $30.00 price objective on the stock. Leerink Partnrs raised ImageneBio to a “strong-buy” rating in a research note on Friday, October 24th. Zacks Research cut ImageneBio from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Finally, Weiss Ratings initiated coverage on ImageneBio in a report on Wednesday, October 22nd. They set a “sell (e-)” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $26.50.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.